Navigation Links
Pharma and food thought leaders set to converge in Amsterdam next April
Date:8/20/2010

Amsterdam, 20 August 2010 - Pharma-Nutrition, the new international scientific conference organised by Elsevier, the leading publisher of scientific, technical and medical information products and services, aims to discuss the latest research, concepts and practical applications of medical nutrition in patient treatments, disease management and patient outcomes. Pharma-Nutrition is set to take place next 18-20 April at Amsterdam's NH Grand Hotel Krasnapolsky. The convergence of both pharmacology and food science professionals, will make this the first platform dedicated to the scientific interface between pharma and food.

The Scientific Committee composed of acknowledged opinion leaders in both food science and pharmacology from across the spectrum of therapeutic research areas will work alongside organisers to develop a multidisciplinary programme, covering areas such as oncology, immunology, neurology and cardiovascular disease. The Conference Chairman, Professor Johan Garssen, University of Utrecht, commented, "We are starting to see a real convergence of the two areas of pharma and food and it is their complementary values which can be applied to medical nutrition in order to help address the ever growing burden of diseases in modern society."

"I am so pleased that we have been able to bring together for the first time such an outstanding group of preclinical and clinical experts from both pharma and nutrition," said Dr. Jaap van Harten, Elsevier Executive Publisher. "This conference will provide the platform for participants to share and discuss their latest research on this important area of science," he remarked.


'/>"/>

Contact: Rachel Martin
r.martin@elsevier.com
31-020-485-2467
Elsevier
Source:Eurekalert

Page: 1

Related biology news :

1. CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
2. Pitt pharmacologists go on a molecular fishing trip and hook prize catch
3. ACS Green Chemistry Institute Pharmaceutical Roundtable award goes to Scottish chemist
4. ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human])
5. Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule
6. URI pharmacy researcher finds beneficial compounds in pure maple syrup
7. NIH awards $8.5 million for research on pharmaceuticals for children
8. TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services
9. GREENBioPharma -- Dec. 2-3, 2009
10. ERGONEX Pharma receives Frost & Sullivans European Orphan Diseases Entrepreneurial Company Award 2009
11. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... , March 2, 2017 Who risk to ... Download the full report: https://www.reportbuyer.com/product/4313699/ ... FINGERPRINT SENSOR FIELD? Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... -- Research and Markets has announced the addition ... their offering. ... The Global Market for Bioproducts Should Reach $714.6 ... CAGR of 8.9%, This research report quantifies ... major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), ...
(Date:3/23/2017)... -- GlobeImmune, Inc. today announced it has entered into a ... of its common stock to NantCell, Inc., a member ... sale of its common stock, NantCell has agreed to ... 200,000 shares, an estimated $2.0 million in value, of ... to enter into this strategic agreement with NantCell," said ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
(Date:3/23/2017)... Colo. , March 23, 2017  Agriculture technology ... Series A financing and note conversion to commercialize its ... Planet is focused on developing products that are simultaneously ... $30 million in the last 18 months. This latest ... North Bridge Venture Partners. The company,s ...
Breaking Biology Technology: